RxDoctor Payments Data

Michael Klug, MD

Internal Medicine · Omaha, NENPI 1093166050

Payments from drug & device makers

$663in general payments, 2019–2025

Across 31 payments — averaging $21.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$226
  • Pfizer$109
  • Novo Nordisk$87
  • Boston Scientific$64
  • Johnson & Johnson$21
  • Biohaven Pharmaceutical Holding Company Ltd.$18
  • plus $140 from 10 others

What the payments were for

  • Food & beverage$65298%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$663 in reported general payments places this provider in the 75th percentile of 570 internal medicine providers in Nebraska.

See all internal medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$287,926
Medicare patients
463
Services billed
5,933

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide178$191,161
EliquisApixaban192$184,637
MounjaroTirzepatide166$183,267
JardianceEmpagliflozin171$172,398
TrulicityDulaglutide23$27,245
MyrbetriqMirabegron26$21,778
JanuviaSitagliptin Phosphate17$13,274
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$9,563
MovantikNaloxegol Oxalate17$6,702
Breo ElliptaFluticasone/Vilanterol14$6,358
Atorvastatin Calcium819$6,349
EntrestoSacubitril/Valsartan11$6,029
SymbicortBudesonide/Formoterol Fumarate25$5,698
Pregabalin138$5,182
Duloxetine Hcl201$4,577

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$226$210,513189 claims
Novo NordiskOzempic$87$191,161178 claims
PfizerEliquis$109$184,637192 claims
Boehringer IngelheimJardiance$17$172,398171 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$11$19,75040 claims
MerckJanuvia$16$13,27417 claims
AstraZenecaSymbicort$14$5,69825 claims
AbbVieSynthroid$14$3,43744 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 570 internal medicine providers in Nebraska.

Other internal medicine in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →